chrisvoncsefalvay/vaers-outcomes huggingface dataset:
having pain from my shoulder; Two days after receiving the injection in my left arm I started having pain from my shoulder to half way down my upper arm; This spontaneous case was reported by a non-health professional and describes the occurrence of ARTHRALGIA (having pain from my shoulder) and VACCINATION SITE PAIN (Two days after receiving the injection in my left arm I started having pain from my shoulder to half way down my upper arm) in a 75-year-old female patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. O4H22A) for COVID-19 prophylaxis.     No Medical History information was reported.    On 05-Jan-2023, the patient received fourth dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Intramuscular) 1 dosage form. On 07-Jan-2023, the patient experienced ARTHRALGIA (having pain from my shoulder) and VACCINATION SITE PAIN (Two days after receiving the injection in my left arm I started having pain from my shoulder to half way down my upper arm). At the time of the report, ARTHRALGIA (having pain from my shoulder) and VACCINATION SITE PAIN (Two days after receiving the injection in my left arm I started having pain from my shoulder to half way down my upper arm) had not resolved.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medications were reported.  It was reported that two days after receiving the injection in left arm patient started having pain from shoulder to half way down upper arm. It has continued to this day. It was unknown if the patient experienced any additional symptoms/events.   No treatment medications were reported.
Extreme inflamation with muscle loss and inability to consume calories to maintain weight due to inflamation
Patient started to have itching on her right side of the neck, then the itching started in the right arm where shot was givien. Patient had redness on the right deltiod. Patient did not have any shortness of breath.  Was given 2 tabs of 25mg benadrly @ 5:40 pm. Patient was watched for 30 mins. Patient did have itching that spread to the whole body.  Patient said last night she cont to have itching all over the body. She took  2 more benadrly @ 10:00 pm. Patient reports that she is still having itching today 01/07/2021. Took a allergy tab in the am.  Patient also reports feeling swollen in the face, neck and hands.
Three minutes after receiving vaccine patient experienced ringing in ear for approximately one minute, dizziness, blurry vision. These symptoms all resolved after four minutes. She then began to experience sore throat and tingling around her mouth which lasted five minutes. All symptoms resolved after 10 minutes. Vital signs stable. No other complaints or issues voiced. No rapid weak pulse, difficulty breathing, shortness of breath, wheezes, stridor, pain with swallowing, cough, chest pain, palpitations, nausea/vomiting, confusion, hives, itchiness, flushing of skin, swelling of lips/tongue, runny nose, or swelling of conjunctiva.
Narrative: COVID infection following COVID vaccine series 03/11, Pfizer, dose #1 04/06, Pfizer, dose #2 11/05/ COVID swab, result: detected 11/05 pt cc: exposure: unknown 11/15 COVID swab, result: NOTdetected
Applies to 1st dose only  on 3/20/21  -       Moderna rash on RT arm at injection site. Redness and hot to touch. ICE pack placed on area and allergy medications taken.   Began to resolve in 24 hours and fully resolved in 72 hours.
Pt developed high fever 102 degrees, lasted for 4 days. Vomited 2x. Diarrhea. Fever diminished. Mac-pap rash appeared.
This spontaneous report as received from a nurse refers to a patient of unknown age and gender. There were no concomitant medications, concurrent condition and medical history reported. On 16-JAN-2015 the patient was vaccinated with VAQTA dose 1, intramuscularly, (strength, dose, frequency, lot number, expiration date and indication were not reported). On 29-APR-2015 the patient was inadvertently administered with VAQTA dose 2, intramuscularly, (strength, dose, frequency, lot number, expiration date and indication were not reported). There was no adverse effects reported. Additional information has been requested.
Patient broke out in a rash covering her trunk approximately 4 hours after receiving injection. Rash lasted approximately a week to ten days.
This spontaneous report was received from a Licensed Practical Nurse and refers to a 2 month old male patient. There were not pertinent medical history, drug reaction allergies or concomitant therapies. The Licensed Practical Nurse reported that on 25-APR-2018, the patient vomited after received the first dose of ROTATEQ orally, lot # N009962, expiration date: 15-NOV-2018, for prophylaxis, (strength, dosage and frequency were not provided). Also, it was stated that ROTATEQ was administered with milk. There were not treatment given for the adverse event, nor laboratories diagnostics were performed. The outcome of vomiting was reported as recovered on an unspecified date in April 2018. The reporter did not provide causality assessment between ROTATEQ and vomiting.
shooting, severe pain in right upper quadrant, followed by rash on left upper back few weeks after second vaccine.  One doctor diagnosed gall bladder problems, cholecystectomy performed.  Pain still there-very severe at times.  Referred to orthodpedic doctors for possible spine involvement.  3 MRI's, 2 CTscans later no diagnosis.   Dermatologist didn't know what rash was.  After 8 months, 9 doctors, friend saw pictures of rash and history of pain and felt that it might be shingles.  Shingles was never considered because shingle vaccination was given 2 years ago.  PCP finally acknowledged that it could be shingles triggered by the COVID vaccines.  Steroids and Lyrica were prescribed and finally pain is receding  But still there from time to tme.  Fatigue is better as well.   will not take any booster vaccines because of this experience.
I tested positive for Covid-19 on March 23, 2023 I experienced fever, sore throat, and tiredness. I was prescribed Paxlovid for my symptoms.
At 1010h, after client received vaccine, her husband then reported to on-site EMS that she was hoarse. Client was evaluated by onsite EMS and per EMS endorsed a headache, difficulty breathing, central back pain, anxiety, and per EMS, was visibly shaking. Client stated that she had NKA and requested that 911 be called. Clients BP was 124/62, PR 69, Pulse Oximetry was 100, RR was 14 and regular. Client was monitored for 30 minutes total, stated that she was "feeling better" as soon as EMS arrived, and refused transportation to the hospital. This nurse called client on 08/09/2021 at 1315h to note any changes in client?s status. The client stated that she did not seek emergency services over the weekend and she continues to have a headache. Client stated that she has left chest pain that started a few minutes after she received her vaccine. Client stated that she is fatigued and tries to walk off the pain but begins to feel dizzy. The client then stated that she feels a ?crushing? sensation in the center of the chest that goes to the left breast. This nurse recommended the client be immediately evaluated for her chest pain at the hospital. The client agreed to seek emergency medical services but declined this nurse?s request to call 911 on her behalf, due to the need to find someone to stay with her minor children. This nurse completed a VAERS report while waiting for the client to find childcare. Client found childcare at 1340h and is having a friend drive her to the Hospital for further evaluation.
My right arm not on injection site but right around injection site hard to touch, painful, itchy and it did not go away; My right arm not on injection site but right around injection site hard to touch, painful, itchy and it did not go away; My right arm not on injection site but right around injection site hard to touch, painful, itchy and it did not go away; This is a spontaneous report from a contactable consumer (patient).  This patient (demographics unknown) received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unknown route, on unknown date at single dose on the right arm for COVID-19 immunisation. No relevant medical history and concomitant medications were provided. The patient stated  'my right arm not on injection site but right around injection site hard to touch, painful, itchy and it did not go away'. The outcome of the events was unknown.  Information about Lot/Batch number has been requested.
Pt recvd 2nd dose of vax & devel burning sensation upon inject as well as soreness & or aching sensation in the arm; pt felt heaviness in the arm;
No signs or symptoms reported.; temperature excursion on VARlVAX - VAQTA that was administered; Information has been received from a medical assistant reporting on a patient of unknown age and gender. There was no information about the patient's concurrent conditions, medical history or concomitant medication.  On 22-APR-2021, the patient was vaccinated with an improperly stored varicella virus vaccine live (Oka/Merck) (VARIVAX) lot#T017687, expiration date 21-MAY-2022 (dose and route of administration were not reported) and with hepatitis A vaccine, inactivated (VAQTA) lot#T023913, expiration date 31-MAR-2022 (dose and route of administration were not reported). Both vaccines for prophylaxis.   On an unknown date, varicella virus vaccine live (Oka/Merck) (VARIVAX) underwent a temperature excursion between 6 degrees Fahrenheit and 14 degrees Fahrenheit for 1 hour and 45 minutes; between 15 degrees Fahrenheit and 46 degrees Fahrenheit for 2 hours and 30 minutes. On an unknown date, hepatitis A vaccine, inactivated (VAQTA) underwent a temperature excursion above 47 degrees Fahrenheit for 2 hours. No previous temperature excursion. The call was not placed due to a digital data logger.  This is one of several reports received from the same reporter. combinationproductreport: Yes; brandname: VAQTA SYRINGE (DEVICE); commondevicename: Hepatitis A Vaccine, Inactivated; productcode: FMF; devicetype: SYRINGE, PISTON (FMF); manufacturername: Merck Sharp & Dohme Corp.; deviceage and unit: 0 ; malfunction: Unknown; deviceusage: Initial; reasonfornoneval: 81 Other; labeledsingleusedevice: No; mdcpreportability: No; mdcpreprationale: Case information does not meet the criteria for Reportability; Sender's Comments:  US-009507513-2104USA007341: US-009507513-2105USA004334:
12 days after Td vaccination, began having deep, burning, achy pain in L deltoid, slightly lower than vaccination site.  Denies redness/swelling.  Still able to use her arm, not sore when moves arm.  States when comparing to other arm "feels odd".  Last Td was >10 years ago.
No additional AE details; TE evaluation states vaccines have been administered to multiple patients; This spontaneous report was received from a certified medical assistant and refers to a 7 year old male patient. No information regarding the patient's medical history, concurrent conditions or concomitant therapies was provided.  On 23-MAR-2022, the varicella virus vaccine live (oka/merck) (VARIVAX) lot number U025790, expiration date: 19-AUG-2023, underwent temperature excursion from -14 Celsius degrees (°C) to -10°C for 3 hours and from -10°C to 8°C for 1 hour and 30 minutes. No previous temperature excursions were reported. Digital Data Logger was used.  On 24-MAR-2022, the patient was vaccinated with the improperly stored dose of varicella virus vaccine live (oka/merck) (VARIVAX) lot number U025790, expiration date: 19-AUG-2023, administered subcutaneously (strength and exact dose were not provided) for prophylaxis (Product storage error). No adverse events were reported (No adverse event).  This is one of several reports from the same reporter.; Sender's Comments:  US-009507513- 2204USA009330:Original Case : 2204USA009330 US-009507513-2205USA003614: US-009507513-2205USA007821: US-009507513-2205USA007847: US-009507513-2205USA007852: US-009507513-2205USA008028: US-009507513-2205USA008004:
Expired Vaccine(MMR 2) administered in error. Exp date: 2/27/21
Pt states that she received the flu shot on 9-28-17. Two weeks later she experienced pain in her left shoulder. She had an Xray and no abnormalities noted. She went back to the Dr. 2 weeks after that with continued discomfort and had a cortisone injection.
No other AE; Improper storage of product in use; This spontaneous report was received from medical assistant and refers to a 13-month-old patient of unknown gender. The patient's medical history and concurrent conditions were not reported. Concomitant medications included sterile diluent.  On 10-JUL-2023, the patient was vaccinated with improperly stored measles, mumps, rubella and varicella (oka-merck) virus vaccine live recombinant Human albumin (rHA) (PROQUAD) injection, unk, lot #W024971, expiration date: 05-FEB-2024, administered for prophylaxis (anatomical location, and route of administration were not provided) (product storage error). Administrated measles, mumps, rubella and varicella (oka-merck) virus vaccine live recombinant Human albumin (rHA) (PROQUAD) was stored at 12.45 Fahrenheit degrees (F) for 20 minutes, previous temperature excursion was reported: 42.31 F for 36 hours and 35 minutes.  There were no adverse events reported (no adverse event).  This is one of several reports received from the same reporter.
Case number PHEH2013US003022 is an initial spontaneous report received from a health care professional on 01 Feb 2013. This report refers to a 16-years-old female patient. It was reported that on an unknown date she inadvertently received only the MENVEO (batch number: A10132) intramuscularly instead of being reconstituted with Men A lyophilized conjugate. No adverse reactions were reported following the administration error.
I started off with a scratchy throat. I ran a high fever of 101-102 degrees. I was able to get in with the doctor a few days later. I had a low-grade fever by then. I have chest congestion and cough. I had a high fever for a few weeks. The doctor diagnosed said I had some type of virus. I tested negative for COVID. I still have congestion and cough now due to high pollen count.
Flublok out of indication was administered to a 14 year old patient with no reported adverse event; Initial information was received on 22-Sep-2022 regarding an unsolicited valid non-serious case received from a other health professional.  This case involves a 14 years old patient with unknown demographics who had experienced an event influenza quadrivalent recombinant vaccine [Flublok QIV] was administered out of indication to a 14 year old patient with no reported adverse event.  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.   On 22-Sep-2022, the patient received a dose of suspect influenza quadrivalent recombinant vaccine (strength, formulation, dose, route, batch number and expiry date: unknown) via intramuscular route for Annual flu shot. Information on batch number was requested.  On 22-SEP-2022 the patient was administered influenza quadrivalent recombinant vaccine out of indication to a 14 year old patient with no reported adverse event (product use issue) (latency: same day).   No lab data was reported  Action taken: not applicable.  Outcome: unknown   This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
pt  felt slightly sweat and had a small amount of dizziness post covid vaccination. Symptoms subsided and pt was released.  BP 131/76 p86 r 18
Diffuse rash from neck to feet, sparing palms and soles starting 6 days after receiving the vaccine. Patient reported they initially looked like small blisters. On my exam about 24 hours after it started, these were pinpoint too numerous to count lesion, some petechial, some coalescing on the backs of the arms and the back that appeared hive-like.
3 of 20 pts recvd Engerix-B 2JUL92 - 3JUL92 & had bad reactions to the vax; all had diaphoresis, tachycardia, & were described as anxious by the reporter; also had dizziness, loss of voice & 1 pt felt like was about to have a sz;
The initial symptom was chest pain and the diagnose is pericarditis. I had the procedure, it was pericardia window. I did have some infusion. They put me on medication for treatment.
Extreme vomiting for more than 6 hours without any prior warning or clues as I?ve experienced in the past
Moderna, Dose: 4, 5 / Pfizer, Dose: 1-3; Treatment of COVID-19; Treatment of COVID-19; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from product quality group. The reporter is the patient.  A 52-year-old female patient (not pregnant) received bnt162b2 (BNT162B2), on 13Jan2021 as dose 1, single (Lot number: EL1284), in left arm, on 05Feb2021 as dose 2, single (Lot number: EL1283), in left arm and on 23Nov2021 as dose 3 (booster), single (Lot number: FH8028) at the age of 50 years, in left arm for covid-19 immunisation; elasomeran (MODERNA COVID-19 VACCINE), on 28Oct2022 as dose 4 (booster), single (Lot number: 056MZIA), in left arm and on 15May2023 as dose 5 (booster), single (Lot number: 5017H22A), in left arm for covid-19 immunisation. The patient's relevant medical history included: "Mild mitral valve prolapse" (unspecified if ongoing); "seasonal allergies" (unspecified if ongoing). The patient's concomitant medications were not reported. The following information was reported: INTERCHANGE OF VACCINE PRODUCTS (medically significant), outcome "unknown", described as "Moderna, Dose: 4, 5 / Pfizer, Dose: 1-3"; VACCINATION FAILURE (medically significant), COVID-19 (medically significant), outcome "not recovered" and all described as "Treatment of COVID-19". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (unspecified date) Positive, notes: Covid-19 treatment; (Nov2023) Positive, notes: Rebound - mild symptoms and positive test on day 12. This was after feeling better for about 4 days. Therapeutic measures were taken as a result of vaccination failure, covid-19. The patient received PAXLOVID as covid treatment from 31Oct2023 to 04Nov2023.
Pt called today 9/17/21 - states she had a flu vaccine (unsure of which one and unsure of lot number) yesterday 9/16/21 done at her facility. She reports she almost collapsed and had difficulty getting out of bed after, was nauseated and extremely weak. Is feeling better today, a little shaky/weak and states her facility nurse is keeping an eye on her.
This spontaneous report as received from a registered nurse refers to a 4 years old patient of unknown gender. On 11-JUL-2014 the patient was vaccinated with M-M-R II (therapy type: rHA, batch number: J005846, lot: 1681AA, expiry date: 17-APR-2015) that on 03/03/2014 was exposed at an unsupported temperature excursion (temperature range: 45F, time frame: 24h). No adverse effect was reported. This is one of several reports received from the same reporter. Additional information has been requested.
Inspiratory and expiratory wheezing, headache, red eyes and fever until 01:00 PM the folowing day
Report 20010119521 described weakness in a 30 year old male who received hep B vaccine (Engerix-B). The vaccinee's allergies, medical history, and concomitant medications wer enot specified. On 04/11/2001, the vaccinee received his first "adult" dose of Engerix-B. Three to four hours post vaccination, he experienced weakness, which resolved within 24 hours. As of 05/14/2001, the event resolved.
11 days after vaccination, I developed a large area (approximately 4 inches) of erythema at the injection site (left deltoid) along with warmth, swelling and itchiness. Also with left sided axillary swelling and pain and left neck pain. Swelling and pain resolved over 24 hours. Redness and itching resolved over 3-4 days.
Patients received the Moderna Covid 19 vaccine after temperature excursion; Patients received the Moderna Covid 19 vaccine after temperature excursion; This spontaneous case was reported by an other health care professional and describes the occurrence of PRODUCT TEMPERATURE EXCURSION ISSUE (Patients received the Moderna Covid 19 vaccine after temperature excursion) and POOR QUALITY PRODUCT ADMINISTERED (Patients received the Moderna Covid 19 vaccine after temperature excursion) in a 19-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 21-May-2022, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .25 milliliter. On 21-May-2022, the patient experienced POOR QUALITY PRODUCT ADMINISTERED (Patients received the Moderna Covid 19 vaccine after temperature excursion). On an unknown date, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (Patients received the Moderna Covid 19 vaccine after temperature excursion). At the time of the report, PRODUCT TEMPERATURE EXCURSION ISSUE (Patients received the Moderna Covid 19 vaccine after temperature excursion) and POOR QUALITY PRODUCT ADMINISTERED (Patients received the Moderna Covid 19 vaccine after temperature excursion) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medication was reported. It was reported storage condition was frozen at the time of the excursion. Lot numbers was reported as 065K21A and 045L21A. Maximum: 30 Fahrenheit degrees minimum -18.9 Fahrenheit degrees temperatures was reached. The vaccines suffered 2 temperature excursions since April, both vaccine was lasted less than 1 minute. It was unknown when the vials moved from freezer to refrigerator. Currently vaccine was stored under frozen state. There was no any visual inspection noting any vaccine state change. No treatment information was reported.   This case was linked to MOD-2022-592921, MOD-2022-592979, MOD-2022-592932, MOD-2022-592958, MOD-2022-592999, MOD-2022-592988, MOD-2022-592873, MOD-2022-592948, MOD-2022-592922, MOD-2022-592920, MOD-2022-592941, MOD-2022-592914, MOD-2022-592972, MOD-2022-592949, MOD-2022-592946, MOD-2022-592879, MOD-2022-593012, MOD-2022-592900, MOD-2022-592965, MOD-2022-592937, MOD-2022-592904, MOD-2022-592924, MOD-2022-592873, MOD-2022-593011, MOD-2022-592913 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 21-Jun-2022: Follow up received contains significant information as patient demographics, vaccine information and event onset date were updated.
Hives, closing of throat, sweeling  of tounge, swollen hands, itchy eyes